Key News
1. Industry associations will recommend setting cost red lines to regulate pricing; the lithium iron phosphate industry is pushing for anti-involution measures.
2. He Lifeng: Continuously promote the improvement of foreign trade quality and efficiency, and remove obstacles to the construction of a unified national market.
Individual Stock News
1. Moore Threads STAR Market IPO: Issue price 114.28 yuan/share, 70 million shares publicly offered, subscription starts on November 24.
2. Pingtan Development: Trading suspension investigation completed, stock resumes trading on the 21st.
3. Strait Innovation: Trading suspension investigation completed, stock resumes trading on the 21st.
4. Hefu China: If the company's stock price rises abnormally further, the company may apply for a trading suspension investigation.
5. Lens Technology: Expects to ship more than 3,000 humanoid robots this year, and expects to double the scale of humanoid robot core component and complete robot assembly by 2026.
6. EVE Energy: Signed a framework agreement with Smoore International for battery cell procurement from 2026 to 2028.
7. Quanyin Hi-Tech: China Seed Group plans to acquire 20% of the company's shares through a tender offer.
8. Shengyi Electronics: Shareholder Dongguan Science and Technology Innovation Investment Group plans to reduce its holdings by no more than 1% of the company's shares.
9. Shenzhen Technology: As a leading domestic high-end memory chip packaging and testing company, its Shenzhen and Hefei packaging and testing facilities are currently operating at full capacity and are expanding production based on recent customer demand.
10. Jinlongyu: Its semi-solid-state series batteries have passed customer testing and received orders.
11. Xinhongze (3 days, 2 limit-up days): During the period of abnormal stock price fluctuations, the controlling shareholder reduced its holdings of the company's shares.
12. Pien Tze Huang: The first subject has been enrolled in the Phase IIa clinical trial of its innovative drug PZH2108 tablets. No drugs with the same target and indication have yet been approved for marketing.
13. Fosun Pharma: Subsidiary's drug included in Breakthrough Therapy Program. Globally, no monoclonal antibody drug targeting PD-1 has been approved for neoadjuvant/adjuvant therapy in gastric cancer.
